Click text to download the following document:
The above data and Data Primer document represent the work of the Biomarkers Consortium Project Use of Targeted Multiplex Proteomic Strategies to Identify Novel Cerebrospinal Fluid (CSF) Biomarkers in AD. This project was submitted to the Biomarkers Consortium Neuroscience Steering Committee by a subgroup of the Alzheimers Disease Neuroimaging Initiative (ADNI) Industry Private Partner Scientific Board (PPSB) for execution and was managed by a Biomarkers Consortium Project Team that includes members from academia, government, foundations and the pharmaceutical industry. Funding for this project was provided by the Alzheimers Drug Discovery Foundation, Eisai, Genentech, Lilly, Merck, Pfizer, and Takeda. This project is the second part of a multi-phased effort seeking to utilize samples collected by ADNI to qualify multiplex panels in both plasma and cerebrospinal fluid (CSF) to diagnose patients with Alzheimers Disease (AD) and monitor disease progression. An earlier phase of the program focused on analysis of data from ADNI plasma samples run on a multiplex panel (Soares et al, in prep, data available on the ADNI website, www.adni.loni.edu).
There are two datasets as well as supporting documentation (Data Primer). The first dataset coded ADNI CSF Multiplex Raw Data includes the original raw data from the run to be intended as reference. The second dataset entitled ADNI CSF QC Multiplex data is the cleaned, quality controlled data according to methodology described in the document.
